The KRAS-variant is a Biomarker of Cetuximab Response and Altered Immunity in Head and Neck Cancer: NRG Oncology/RTOG 0522

Authors :: Rita Axelrod
Christine H. Chung
Adel K. El-Naggar
Allen M. Chen
Andy Trotti
Jonathan Harris
Q. Zhang
Dörthe Schaue
Chance Matthiesen
V. Avizonis
Phuc Felix Nguyen-Tan
David Raben
Anurag K. Singh
Omar Yumen
Joanne B. Weidhaas
Thomas J. Galloway
Heath D. Skinner
David Sidransky
Robert L. Ferris
R.K. Chin
Demin Wang
R. Manon
James Sayre
Source :: International Journal of Radiation Oncology*Biology*Physics. 96:941-942
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Radiation
Cetuximab
business.industry
Head and neck cancer
Altered immunity
medicine.disease
medicine.disease_cause
Internal medicine
medicine
Biomarker (medicine)
Radiology, Nuclear Medicine and imaging
KRAS
business
medicine.drug

Full Text Access

Tools